Effect of hepatitis A vaccination programs

JAMA

Volumn 294, Issue 2, 2005, Pages 246-248

  Van Damme, Pierre ^a   Van Herck, Koen ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

AGE DISTRIBUTION; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EPIDEMIOLOGICAL DATA; HEALTH PROGRAM; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INCIDENCE; INDUSTRIALIZATION; INFECTION SENSITIVITY; PRIORITY JOURNAL; VACCINATION; NOTE; PREVENTIVE HEALTH SERVICE; STATISTICS;

HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; VACCINATION;

EID: 22144441367     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.2.246     Document Type: Editorial

References (21)

1. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48:1-37.
2. Eurohep.net surveillance of vaccine preventable hepatitis Web site. Available at: http://www.eurohep.net. Accessed May 29, 2005.
3. Health Protection Agency Web site. European sero-epidemiology network 2. Available at: http://www.hpa.org.uk/hpa/inter/esen2_menu.htm. Accessed May 29, 2005.
4. André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines. 2002;1:9-23.
5. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327:453-457.
6. Vidor E, Dumas R, Porteret V, Bailleux F, Veitch K. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis. 2004;23:300-309.
7. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet. 1994;343:322-334.
8. Mao JS, Chai SA, Xie RY, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine. 1997;15:944-947.
9. Black S, Shinefield H, Hansen J, et al. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine. 2004;22:766-772.
10. Bell BP, Feinstone SM. Hepatitis A vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, Pa: WB Saunders Co; 2004:269-297.
11. Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect. 2004;49:179-209.
12. Van Damme P, Banatvala J, Fay O, et al; for the International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? Lancet. 2003;362:1065-1071.
13. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328-1334.
14. Perez OM, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis. 2003;188:671-677.
15. World Health Organization. Hepatitis A vaccines. Wkly Epidemiol Rec. 2000;75:38-44.
16. Lopalco PL, Salleras L, Barbuti S, et al. Hepatitis A and B in children and adolescents: what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine. 2001;19:470-474.
17. Dominguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in pre-adolescents. Vaccine. 2003;21:698-701.
18. MacIntyre CR, Burgess MA, Hull B, McIntyre P. Hepatitis A vaccination options for Australia: review article. J Paediatr Child Health. 2003;39:83-87.
19. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194-201.
20. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294:202-210.
21. Gay NJ. A model of long-term decline in the transmissibility of an infectious disease: implications for the incidence of hepatitis A. Int J Epidemiol. 1996;25:854-861.